- Upon closing, Arrowhead will receive $825 million immediately, including an upfront payment and an equity investment at a 35% premium, and will receive an additional $250 million paid over five ...

This collaboration creates a path for accelerating our respective oncology pipeline programs and broadening the use of Autolus’ technology outside of autologous cell therapy applications.” BioNTech ...

Artiva Biotherapeutics, Inc., an oncology company focused on developing and commercializing primary allogeneic natural killer (NK) cell therapies to treat cancer, announced today that it has entered ...

SAN DIEGO and SUZHOU, China, May 04, 2023 (GLOBE NEWSWIRE) -- Adagene Inc. (ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel ...

STARKVILLE, Miss.—Mississippi State University is beginning an international education collaboration with Brazil’s Universidade de Rio Verde after the signing of a joint agreement this week. MSU ...

CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK 01.11.2023 / 13:00 CET/CEST The issuer is solely responsible for the ...

Ahold USA, Inc., parent company supermarkets Giant Landover, Stop & Shop New England, Stop & Shop New York Metro, Giant Carlisle and online grocery Peapod, has partnered with Retail Solutions Inc.

Last year I met with a woman while she was jailed in an immigration detention site near Miami, Florida. She told me about her 5-month-old baby, whom she hadn’t seen in three months. She said that her ...

From cooperation to evidence-based positions on scope and search, a UF Law E-Discovery Conference panel shared some of the best practices to successfully preserve collaboration app data. For every ...

– Sarepta obtains exclusive worldwide licenses to four clinical-stage and three preclinical-stage programs in muscle, central nervous system, and rare pulmonary disorders, including potential ...

MAINZ, Germany and LONDON, United Kingdom, February 8, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech”), a next-generation immunotherapy company pioneering novel therapies for cancer and other serious ...